Arch Therapeutics, Inc.

OTCPK:ARTH Stock Report

Market Cap: US$912.0k

Arch Therapeutics Past Earnings Performance

Past criteria checks 0/6

Arch Therapeutics's earnings have been declining at an average annual rate of -16.3%, while the Medical Equipment industry saw earnings growing at 12% annually. Revenues have been growing at an average rate of 77.7% per year.

Key information

-16.3%

Earnings growth rate

13.4%

EPS growth rate

Medical Equipment Industry Growth8.9%
Revenue growth rate77.7%
Return on equityn/a
Net Margin-8,769.2%
Last Earnings Update30 Jun 2024

Recent past performance updates

No updates

Recent updates

Revenue & Expenses Breakdown

How Arch Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

OTCPK:ARTH Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 240-1341
31 Mar 240-841
31 Dec 230-851
30 Sep 230-741
30 Jun 230-641
31 Mar 230-641
31 Dec 220-641
30 Sep 220-551
30 Jun 220-551
31 Mar 220-651
31 Dec 210-751
30 Sep 210-651
30 Jun 210-651
31 Mar 210-541
31 Dec 200-441
30 Sep 200-542
30 Jun 200-442
31 Mar 200-542
31 Dec 190-442
30 Sep 190-542
30 Jun 190-553
31 Mar 190-653
31 Dec 180-853
30 Sep 180-553
30 Jun 180-643
31 Mar 180-653
31 Dec 170-652
30 Sep 170-852
30 Jun 170-752
31 Mar 170-752
31 Dec 160-652
30 Sep 160-642
30 Jun 160-642
31 Mar 160-542
31 Dec 150-442
30 Sep 150-342
30 Jun 150-132
31 Mar 150132
31 Dec 140-732
30 Sep 140-831
30 Jun 140-1031
31 Mar 140-1131

Quality Earnings: ARTH is currently unprofitable.

Growing Profit Margin: ARTH is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: ARTH is unprofitable, and losses have increased over the past 5 years at a rate of 16.3% per year.

Accelerating Growth: Unable to compare ARTH's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ARTH is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (12.9%).


Return on Equity

High ROE: ARTH's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 02:07
End of Day Share Price 2024/12/24 00:00
Earnings2024/06/30
Annual Earnings2023/09/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Arch Therapeutics, Inc. is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Raghuram SelvarajuH.C. Wainwright & Co.
Michael HigginsLadenburg Thalmann & Company
Raghuram SelvarajuRodman & Renshaw, LLC